| Audience | Cannabis Clinicians, Patients Using CBD, Researchers |
| Primary Topic | CBD Effects on Appetite and Energy Balance |
| Source | Read the full article |
CBD Increased Food Intake in Healthy Adults Despite Lower Ghrelin Levels
A controlled human trial reveals that cannabidiol significantly increased energy intake at lunch by nearly 200 calories while paradoxically suppressing the hunger hormone ghrelin, challenging common assumptions about CBD’s appetite-dampening effects and raising questions about alternative appetite pathways.
| Study Type | Randomized, double-blind, placebo-controlled crossover trial |
| Population | Fifteen healthy adults (11 males, 4 females), mean age 25 years, mean BMI 24.3 kg/m² |
| Exposure or Intervention | Single oral dose of 298 mg CBD isolate |
| Comparator | Matched placebo |
| Primary Outcomes | Ad libitum energy intake at lunch 180 minutes post-dose; postprandial glucose and lipid metabolism |
| Sample Size or Scope | N=15 participants in crossover design |
| Journal | Appetite |
| Year | 2026 |
| DOI | 10.1016/j.appet.2026.108531 |
| Funding or Conflicts | National Centre for Sport and Exercise Medicine, Loughborough University; NIHR Leicester Biomedical Research Centre |
Researchers tested whether acute CBD ingestion affects energy intake, subjective appetite, or postprandial glucose and lipid metabolism in healthy adults. Participants consumed either CBD or placebo, ate a standardized breakfast 30 minutes later, and had blood drawn hourly for metabolic and hormonal analysis. At 180 minutes post-dose, participants were offered an ad libitum pasta lunch and instructed to eat until comfortably full. The primary outcome was total caloric consumption at that meal.
Participants consumed 193 kilocalories more at lunch after CBD ingestion compared to placebo (979 kcal vs 786 kcal, p=0.003), representing a 25% increase in energy intake. The effect size was large (Cohen’s d=0.94). Ghrelin concentrations were significantly lower following CBD at both 120 and 180 minutes, and the minimum ghrelin level and area under the curve were also reduced compared to placebo. Despite this biochemical signal for reduced hunger, there were no differences in subjective appetite ratings (hunger, fullness, desire to eat) between conditions. Postprandial glucose, triglycerides, non-esterified fatty acids, insulin, GLP-1, energy expenditure, and substrate oxidation rates were all similar between CBD and placebo conditions.
This is a well-designed randomized controlled crossover trial with appropriate blinding, standardized conditions, and objective measurement of food intake. The crossover design strengthens internal validity by using participants as their own controls. The effect is robust (large effect size, statistically significant). However, the small sample size (N=15), homogeneity of the population (mostly young, healthy males), and single-dose acute design limit external validity and prevent assessment of dose-response relationships or longer-term effects.
The study tested only a single dose on a single day in each condition. We do not know whether this effect persists with repeated dosing, whether tolerance develops, or what the dose-response curve looks like. The population was young, healthy, and predominantly male. These findings may not generalize to older adults, those with metabolic disease, patients with appetite disorders, or clinical populations using CBD therapeutically. The mechanism remains unknown. The researchers offer no explanation for why CBD would increase eating while simultaneously lowering ghrelin and not affecting subjective hunger. The meal was self-selected pasta, and food preferences or macronutrient-specific effects were not assessed. Finally, the study did not measure CBD plasma concentrations, so we cannot confirm bioavailability or relate blood levels to effects.
This well-executed trial provides the first human evidence that acute CBD administration can increase food consumption, challenging assumptions derived from animal models. The magnitude of the effect is clinically meaningful (200 kilocalories represents 10-25% of typical lunch intake), and the paradoxical suppression of ghrelin alongside increased eating reveals gaps in our mechanistic understanding. However, the small sample size, single-dose design, and healthy population limit generalizability. Clinicians should incorporate these findings into patient counseling about CBD’s potential effects on appetite and weight, acknowledging uncertainty and monitoring individual responses rather than applying categorical predictions. Future research must address dose-response relationships, chronic effects, clinical populations, and the underlying mechanisms driving this unexpected orexigenic signal.
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Frequently Asked Questions
Does CBD increase or decrease appetite?
The answer appears more complex than previously thought. This controlled trial in healthy adults showed CBD increased food intake by about 200 calories at a single meal, contradicting animal studies showing appetite suppression. However, we do not yet know whether this effect persists with repeated use, varies by dose, or occurs in all populations. Clinical observations suggest CBD’s appetite effects may be bidirectional or context-dependent. More research is needed before making definitive claims.
Why did participants eat more despite lower ghrelin levels?
This is one of the study’s most intriguing mysteries. Ghrelin is known as the hunger hormone and typically stimulates appetite when elevated. CBD suppressed ghrelin but increased eating, suggesting alternative appetite pathways are at play. Possibilities include effects on reward circuitry, hedonic eating behavior, endocannabinoid signaling independent of ghrelin, or metabolic signals we have not yet identified. The mechanism remains unknown and warrants further investigation.
Should patients using CBD for other conditions worry about weight gain?
Not necessarily. This study measured a single meal after a single dose in healthy volunteers. We do not know whether repeated CBD use leads to sustained increased caloric intake or actual weight gain over time. Many patients use CBD chronically without reporting weight changes. However, clinicians and patients should monitor appetite and weight when starting CBD, particularly at higher doses, and adjust treatment if unwanted changes occur. Individual responses vary considerably.
How does this compare to THC’s well-known appetite effects?
THC reliably increases appetite through CB1 receptor activation, producing subjective hunger and increased food intake. This study did not compare CBD directly to THC, so we cannot make definitive statements about relative magnitude or mechanisms. However, the fact that CBD increased eating without increasing subjective hunger suggests different pathways may be involved. THC’s appetite effects are mediated by CB1 receptors in hypothalamic circuits, whereas CBD has low affinity for CB1 and may act through alternative mechanisms.
What dose of CBD was used in this study?
Participants received 298 mg of CBD isolate as a single oral dose. This is a moderate to high dose compared to typical CBD products marketed for wellness (which often contain 10-50 mg per dose), but within the range used in some clinical trials for therapeutic indications. We do not know whether lower doses would produce similar effects or whether a dose-response relationship exists. The study did not measure CBD blood levels, so we cannot relate plasma concentrations to outcomes.
Could CBD be useful for treating appetite loss or cachexia?
This study raises the possibility but does not establish clinical utility. The trial enrolled healthy young adults, not patients with appetite disorders, cancer-related cachexia, or wasting syndromes. Effects in disease states may differ substantially from effects in healthy populations. Additionally, a single-meal increase in caloric intake does not guarantee sustained nutritional benefit or weight gain over time. Controlled trials in relevant patient populations would be needed to determine whether CBD has therapeutic value for appetite stimulation.
Did CBD affect metabolism or how the body processes food?
No. The study found no differences between CBD and placebo in postprandial glucose, triglycerides, insulin, GLP-1, energy expenditure, or rates of carbohydrate and fat oxidation. CBD increased the amount of food consumed but did not alter how the body metabolized that food. This suggests the effect is on appetite regulation or eating behavior rather than metabolic processing.
Why did participants not report feeling hungrier if they ate more?
This is another unresolved question from the study. Subjective hunger ratings (measured by visual analog scales assessing hunger, fullness, and desire to eat) did not differ between CBD and placebo conditions, yet participants consumed significantly more calories after CBD. This disconnect between subjective experience and actual eating behavior suggests CBD may influence food intake through pathways that bypass conscious hunger perception, potentially involving reward, palatability, satiety signaling, or other mechanisms not captured by standard appetite questionnaires.
